ER heart test feedback aims to cut readmissions and deaths in Rapid-Breathing patients
NCT ID NCT05699564
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving doctors early results from heart biomarker tests (NT-proBNP and hs-cTnT) along with a structured interpretation note can improve outcomes for patients admitted with rapid breathing (tachypnea). About 574 adults will be randomly assigned to receive this feedback or standard care. The main goal is to see if the feedback extends the time until a patient is readmitted to the hospital or dies from any cause.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- early biomarker testing (NT-proBNP and hs-cTnT) with structured feedback
- What this could lead to
- If successful, this could show that early biomarker-guided assessments in the ER help reduce hospital readmissions and deaths in patients with rapid breathing.
- What could go wrong
- This is a single-center pragmatic trial, not a large Phase 3 study. The intervention is informational feedback, not a drug, so the impact may be modest and may not apply to other hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
574 people
The number who actually took part.
- Started
-
Mar 2023
- Expected to finish
-
Dec 2038
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients ≥18 years old * Tachypnea (respiratory rate ≥20/min) * Admission to Departments under the Division of Medicine at Akershus University Hospital, except the Department of Neurology * \<24 h from hospital admittance to inclusion in the study * Signed written informed consent during the initial phase of the hospitalization Exclusion Criteria: * Previously included into the study (in case of patients presenting with a second hospitalization during the study period) * Known or suspected cancer outside of local control, documented in medical records, at the time of patient inclusion or diagnosed in relation to the index hospitalization * Neurological condition with short life expectancy; e.g. ALS, documented in medical records during screening prior to study entry * Other non-cardiac disease with life expectancy below 1 year, documented in medical records during screening prior to study entry * Obvious non-cardiac cause for tachypnea based on medical records and clinical findings during screening prior to study entry; e.g. anaphylaxis in young patient with known allergy, dyspnea after direct chest trauma, or young patient with fever and positive Covid-19 test on admission. * Patient assessed as non-Internal Medicine patient; e.g. surgical patient * Patients unwilling or unable to comply with the protocol, including Glasgow Coma Scale \<13 on the time of study inclusion * Patients that are intubated for invasive ventilatory therapy before or shortly after hospital admission * History of non-compliance to medical management and patients who are considered potentially unreliable, based on documentation in medical records, during screening prior to study entry * History or evidence of alcohol or drug abuse with the last 12 months, based on medical records and clinical findings during screening prior to study entry, that will influence study participation * Any surgical or medical condition, based on medical records and clinical findings during screening prior to study entry, that will impair the ability of the patient to participate in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Akershus University Hospital
Lørenskog, Lørenskog, 1478, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?
- Can AI read heart ultrasounds as well as trained sonographers?
- Can modern heart failure drugs reverse damage in three months?